NO20031860L - Kahalalid F - Google Patents

Kahalalid F

Info

Publication number
NO20031860L
NO20031860L NO20031860A NO20031860A NO20031860L NO 20031860 L NO20031860 L NO 20031860L NO 20031860 A NO20031860 A NO 20031860A NO 20031860 A NO20031860 A NO 20031860A NO 20031860 L NO20031860 L NO 20031860L
Authority
NO
Norway
Prior art keywords
kahalalid
kahalalide
formulations
Prior art date
Application number
NO20031860A
Other languages
English (en)
Other versions
NO20031860D0 (no
NO331082B1 (no
Inventor
Graham Keith Ruffles
Glynn Thomas Faircloth
Bastian Nuyen
Steve Weitman
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20031860D0 publication Critical patent/NO20031860D0/no
Publication of NO20031860L publication Critical patent/NO20031860L/no
Publication of NO331082B1 publication Critical patent/NO331082B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NO20031860A 2000-10-31 2003-04-25 Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft NO331082B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US24622900P 2000-11-06 2000-11-06
US34844901P 2001-10-19 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en) 2000-10-31 2001-10-31 Kahalalide f formulation

Publications (3)

Publication Number Publication Date
NO20031860D0 NO20031860D0 (no) 2003-04-25
NO20031860L true NO20031860L (no) 2003-06-30
NO331082B1 NO331082B1 (no) 2011-10-03

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031860A NO331082B1 (no) 2000-10-31 2003-04-25 Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft

Country Status (22)

Country Link
US (1) US7473681B2 (no)
EP (1) EP1330258B1 (no)
JP (2) JP2004512370A (no)
KR (1) KR100834138B1 (no)
CN (1) CN1568192A (no)
AT (1) ATE314084T1 (no)
AU (2) AU1074902A (no)
BR (1) BR0114912A (no)
CA (1) CA2425627A1 (no)
CY (1) CY1105009T1 (no)
CZ (1) CZ20031211A3 (no)
DE (1) DE60116359T2 (no)
DK (1) DK1330258T3 (no)
ES (1) ES2256305T3 (no)
HK (1) HK1054192B (no)
HU (1) HUP0600031A3 (no)
IL (2) IL155297A0 (no)
MX (1) MXPA03003704A (no)
NO (1) NO331082B1 (no)
NZ (1) NZ525243A (no)
SK (1) SK286421B6 (no)
WO (1) WO2002036145A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2002334203C1 (en) * 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
KR20110114690A (ko) * 2002-10-18 2011-10-19 파르마 마르 에스.에이.유. 4-메틸헥사노 카할라리드 ｆ 화합물
CN100591691C (zh) * 2002-10-18 2010-02-24 马尔药品公司 新型抗肿瘤化合物
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CA2582452C (en) * 2004-10-26 2010-09-07 Erard Gilles Pegylated liposomal doxorubicin in combination with ecteinascidin 743
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
US20110015135A1 (en) * 2008-03-07 2011-01-20 Pharma Mar S.A. Antitumoral Treatments
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
EP0827751B1 (en) 1996-09-06 2003-02-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal composition containing tissue plasminogen activator and nicotinamide
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
AP2001002113A0 (en) 1998-09-23 2001-06-30 Marcus Keep Neuroimmunophilins for selective neuronal radioprotection.
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
IL155297A0 (en) 2003-11-23
MXPA03003704A (es) 2004-05-04
DE60116359D1 (de) 2006-02-02
HUP0600031A2 (en) 2006-05-29
JP2010047601A (ja) 2010-03-04
US20040067895A1 (en) 2004-04-08
SK5022003A3 (en) 2003-12-02
AU1074902A (en) 2002-05-15
CN1568192A (zh) 2005-01-19
CA2425627A1 (en) 2002-05-10
NZ525243A (en) 2005-01-28
WO2002036145A8 (en) 2003-10-23
CZ20031211A3 (cs) 2003-09-17
BR0114912A (pt) 2003-10-14
WO2002036145A2 (en) 2002-05-10
HK1054192B (zh) 2006-09-08
DK1330258T3 (da) 2006-05-22
AU2002210749B2 (en) 2006-12-21
DE60116359T2 (de) 2006-09-28
IL155297A (en) 2010-05-31
ATE314084T1 (de) 2006-01-15
NO20031860D0 (no) 2003-04-25
SK286421B6 (sk) 2008-09-05
JP2004512370A (ja) 2004-04-22
EP1330258A2 (en) 2003-07-30
KR100834138B1 (ko) 2008-06-02
EP1330258B1 (en) 2005-12-28
ES2256305T3 (es) 2006-07-16
NO331082B1 (no) 2011-10-03
HUP0600031A3 (en) 2012-02-28
CY1105009T1 (el) 2010-03-03
WO2002036145A3 (en) 2002-10-17
US7473681B2 (en) 2009-01-06
PL360848A1 (en) 2004-09-20
HK1054192A1 (en) 2003-11-21
KR20030044005A (ko) 2003-06-02

Similar Documents

Publication Publication Date Title
NO20031860D0 (no) Kahalaolid F
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE264863T1 (de) 28-epirapaloge
MXPA03005769A (es) Politrimetilen eter ester amida y uso de la misma.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
ATE330017T1 (de) Kallikrein gen
HK1071152A1 (en) Silicone rubber formulations and the use thereof
DOP2001000219A (es) Applicator
BR0110577A (pt) Decorina transgenicamente produzida
AU144678S (en) Bottle
AR030853A1 (es) Composicion plaguicida
BR0110902A (pt) Inibidores de mmp-9/mmp-2
MXPA02007173A (es) Compuestos calciliticos.
NO20005548L (no) Mykobakterieinhibitorer
DE60124148D1 (de) Kalzilytische verbindungen
BR0316544A (pt) Compostos calcilìticos
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
ATE433953T1 (de) Peptiddeformylaseinhibitoren
UA50030A (uk) Комплексне добриво
ES1049942Y (es) Pareja de zocalo y portalamparas.
AU144369S (en) Tube applicator
BR8002983U (pt) Beliche guarda-roupa e escrivaninha
JO2151B1 (en) Toilet (T.S)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees